-
Product Insights
Punta Senillosa NC Field, Argentina
Punta Senillosa NC upstream field is located in Neuquen Province, Argentina. The upstream field is owned by Tecpetrol SA. It is operated by Tecpetrol SA. The project started its operations in 2016. Punta Senillosa NC Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also...
-
Product Insights
Las Chivas NC Field, Argentina
Las Chivas NC upstream field is located in Neuquen Province, Argentina. The upstream field is owned by Tecpetrol SA. It is operated by Tecpetrol SA. The project started its operations in 2016. Las Chivas NC Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also...
-
Product Insights
NC 41–Mellitah Gas Pipeline, Libya
NC 41–Mellitah Gas is located in Bay of Tripoli, Libya. The pipeline is owned by Eni SpA (50%); National Oil Corp (50%). It will be operated by Mellitah Oil & Gas BV. The project is currently in the announced stage and is expected to start operations in 2025. NC 41–Mellitah Gas Pipeline profile includes core details such as name, location (start and end points and route points), pipeline type, asset status, start year, owner and equity stakes, operator, length, diameter,...
-
Product Insights
NC 41–Mellitah Condensate Pipeline, Libya
NC 41–Mellitah Condensate is located in Bay of Tripoli, Libya. The pipeline is owned by Eni SpA (50%); National Oil Corp (50%). It will be operated by Mellitah Oil & Gas BV. The project is currently in the announced stage and is expected to start operations in 2025. NC 41–Mellitah Condensate Pipeline profile includes core details such as name, location (start and end points and route points), pipeline type, asset status, start year, owner and equity stakes, operator, length, diameter,...
-
Product Insights
Abu Attifel and NC 125 Field, Libya
Abu Attifel and NC 125 upstream field is located in Al Wahat, Libya. The upstream field is owned by Eni North Africa BV (50%); Mellitah Oil & Gas BV (0%); National Oil Corp (50%). It is operated by Mellitah Oil & Gas BV. The project started its operations in 1972. Abu Attifel and NC 125 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-410 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NC-410 in Cervical Cancer Drug Details: NC-410 is under development for the treatment of metastatic solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-410 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NC-410 in Gastric Cancer Drug Details: NC-410 is under development for the treatment of metastatic solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-410 in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NC-410 in Esophageal Cancer Drug Details: NC-410 is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-410 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NC-410 in Ovarian Cancer Drug Details: NC-410 is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-410 in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NC-410 in Endometrial Cancer Drug Details: NC-410 is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-410 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NC-410 in Solid Tumor Drug Details: NC-410 is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-410 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NC-410 in Colorectal Cancer Drug Details: NC-410 is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-762 in Prostate Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NC-762 in Prostate Cancer Drug Details:NC-762 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-762 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NC-762 in Pancreatic Cancer Drug Details:NC-762 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-762 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NC-762 in Solid Tumor Drug Details:NC-762 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-762 in Endometrial Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NC-762 in Endometrial Cancer Drug Details:NC-762 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-762 in Hepatocellular Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NC-762 in Hepatocellular Carcinoma Drug Details:NC-762 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-762 in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NC-762 in Ovarian CancerDrug Details:NC-762 is under development for the treatment of solid tumors including non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-525 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NC-525 in Myelodysplastic SyndromeDrug Details:NC-525 is under development for the treatment of relapsed and refractory acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-410 in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NC-410 in Gastroesophageal (GE) Junction Carcinomas Drug Details: NC-410 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.